Please assess the completion status of the following clinical trial:

Trial Title: Evaluation of Ezetimibe and Atorvastatin Coadministration Versus Atorvastatin or Rosuvastatin Monotherapy in Japanese Patients With Hypercholesterolemia (Study P06027)(COMPLETED)

Study Design Characteristics:
- Allocation: RANDOMIZED
- Intervention Model: PARALLEL
- Observational Model: None
- Primary Purpose: TREATMENT
- Time Perspective: None
- Masking: NONE
- Phase: PHASE4
- Number of Arms: 3.0

Eligibility Criteria:
Inclusion Criteria:~* atorvastatin 10 mg monotherapy for 4 weeks or longer before the start of the 4-week washout and low density lipoprotein-cholesterol (LDL-C) levels that had not reached the following lipid management target values during treatment: Category I (low-risk group) with no other risk factors - LDL-C \<160 mg/dL; Category II (mid-risk group) with 1-2 risk factors other than LDL-C levels - LDL-C \<140 mg/dL; Category III (high-risk group) with 3 or more other risk factors - LDL-C \<120 mg/dL; and for participants with history of coronary artery disease - LDL-C \<100 mg/dL.~* outpatient men or women, age 20 years and older~Exclusion Criteria:~* fasted triglyceride level at the start of washout or treatment period exceeding 400 mg/dL.~* homozygous familial hypercholesterolemia.~* creatine phosphokinase (CPK) \>2 times the upper limit of normal (X ULN) at start of washout or treatment period.~* glycosylated hemoglobin (HbA1c) \>=8％ at start of washout or treatment period.~* severe hepatic function disorder, or aspartate aminotransferase (AST) or alanine aminotransferase (ALT) \>2X ULN at start of washout or treatment period.~* hypersensitivity to ezetimibe, atorvastatin, or rosuvastatin tablets.~* pregnant or lactating~* discontinued use of atorvastatin 10 mg for less than 4 weeks at start of treatment period (however, if participant had taken atorvastatin 10 mg before the test conducted at the start of the observation period, a period of discontinuation of 27 days is allowed.)~* cyclosporine treatment~* hyperlipidemia associated with hypothyroidism, obstructive gall bladder or biliary disease, chronic renal failure, and/or pancreatitis.~* hyperlipidemia associated with drug administration that causes adverse serum lipid effects.~* participation in a clinical study within 4 weeks of washout~* cancer or cancer history within previous 5 years, except for successfully treated basal cell carcinoma of the skin.

- Gender: ALL
- Minimum Age: 20 Years
- Maximum Age: None
- Healthy Volunteers: f

Study Arms:
- Ezetimibe + Atorvastatin (Type: EXPERIMENTAL): Participants with hypercholesterolemia receiving atorvastatin 10 mg and ezetimibe 10 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
- Atorvastatin (Type: ACTIVE_COMPARATOR): Participants with hypercholesterolemia receiving atorvastatin 20 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg
- Rosuvastatin (Type: ACTIVE_COMPARATOR): Participants with hypercholesterolemia receiving rosuvastatin 2.5 mg for 12 weeks after a 4-week washout and 4 weeks of daily atorvastatin 10 mg

Based on this trial design, predict the completion outcome and termination type (if applicable).